Cellyan Biotechnology Co., Ltd HKPD

Industrials SIC 5122 - Wholesale-Drugs, Proprietaries & Druggists' Sundries NAICS Wholesale Trade › Merchant Wholesalers, Nondurable Goods › Drugs and Druggists' Sundries Merchant Wholesalers derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2026FY2024FY2023FY2022FY2021
Revenue —$20.3M$16.7M$12.6M—
Operating income —-$2.3M-$2.0M-$1.8M—
Net income —-$27.1K$1.3M$998.2K—

Balance sheet

Fiscal year FY2026FY2024FY2023FY2022FY2021
Total assets —$9.4M$8.7M——
Total equity —$5.0M$4.3M$585.2K-$413.6K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-086725.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -10M 0 10M 20M 30M Revenue, FY2022: 12.6M Net income, FY2022: 998.2K Revenue, FY2023: 16.7M Net income, FY2023: 1.3M Revenue, FY2024: 20.3M Net income, FY2024: -27.1K FY2021 FY2022 FY2023 FY2024 FY2026
Fiscal year FY2021FY2022FY2023FY2024FY2026
Revenue — $12.6M $16.7M $20.3M —
Gross profit — — — — —
Net income — $998.2K $1.3M -$27.1K —

Others in SIC 5122

TickerCompanyMarket capP/ERevenue growth
MCK MCKESSON CORP $116.68B 26.1x 12.4%
COR Cencora, Inc. $63.16B 41.6x 9.3%
CAH CARDINAL HEALTH INC $58.04B 34.5x 14.2%
HLF HERBALIFE LTD. $1.40B 6.1x 0.9%
NUS NU SKIN ENTERPRISES, INC. $233.2M 1.5x -14.3%
COSM Cosmos Health Inc. $26.3M — 19.9%
HWH HWH International Inc. $20.7M — -30.8%
MEDS DataMeds AI, Inc. $6.8M — 28.7%